Cresco Labs +19%: US MSOs Rally Hard After Marijuana Rescheduling

A wave of buying swept through US cannabis equities this week as multi-state operators digested the Department of Justice's April 23 Schedule III order. The Cresco Labs stock surge of roughly 19% on Tuesday led the move, with Green Thumb Industries up 13.85%, Jushi Holdings up 12.43%, and Ascend Wellness Holdings up 11.26% — a coordinated bid across the largest US MSOs that hadn't been seen since the original rescheduling proposal in 2024.

For an industry that spent most of 2024 and 2025 grinding sideways, the rally is the cleanest signal yet that institutional capital is pricing in the federal tax relief, capital-markets access, and broader policy normalization that Schedule III is starting to deliver. But seasoned cannabis investors are also doing the harder work of separating the rescheduling-driven move from the fundamental headwinds that haven't gone away.

The Tax Math Driving the Rally

The single biggest fundamental change is the elimination of Internal Revenue Code Section 280E for state-licensed medical cannabis operations, effective April 22, 2026. Since the 1980s, 280E has prevented businesses trafficking in Schedule I or II controlled substances from deducting normal operating expenses, leaving cannabis companies with effective federal tax rates often north of 70%.

For the major MSOs, the math is dramatic. Curaleaf told analysts that for the 2025 fiscal year, the company estimates it would have saved approximately $116 million on taxes if rescheduling had been in effect. Green Thumb Industries projected savings in the $80 to $100 million range. Trulieve, with the largest medical operation in Florida, has guided to $90 million-plus in annual savings. Across the top five MSOs, total annual 280E relief is approaching $500 million.

That money translates almost immediately into free cash flow improvement. Cantor Fitzgerald's cannabis team estimates that 2026 free cash flow at the top US MSOs will roughly double versus 2025 baseline, with most of the lift coming in the second half as operators complete federal registration and book the tax savings. For companies that had been bleeding cash and burning through credit lines, the change is genuinely transformative.

Why Cresco Led the Tape

Cresco Labs' 19% Tuesday move was the largest among the top tier and reflects several company-specific factors. Cresco has the cleanest medical-state footprint of the major MSOs, with a heavy concentration in Pennsylvania, Ohio, and Illinois — three states where Schedule III medical registration should move quickly. The company also has higher 280E exposure as a percentage of revenue than peers, meaning the tax relief flows more directly to its bottom line.

Cresco's balance sheet is another factor. After completing its Columbia Care merger and selling non-core assets in 2024, the company entered 2026 with a tighter cost structure and more capacity to absorb the operational complexity of federal registration. Several Wall Street notes flagged Cresco as a "first-mover" candidate likely to file with the DEA in the early days of the 60-day priority window.

Green Thumb Industries' 13.85% move was also notable for a different reason: GTI is widely viewed as the operationally strongest US MSO, and it is the rare cannabis large-cap that has been consistently free-cash-flow positive. The rally there suggests investors are pricing in not just tax savings but also the prospect of capital markets access that GTI may finally be able to use to consolidate the industry.

What the ETF Tape Says

The MSOS ETF, the largest pure-play vehicle for US cannabis exposure, posted one of its strongest one-week moves of the past two years. The fund tracks the AdvisorShares Pure US Cannabis index, which is heavily weighted toward the same MSO names that led Tuesday's session.

Volumes told a deeper story. MSOS traded more than 4x its 30-day average daily volume during the rescheduling-news week, a clear sign that institutional buyers — not just retail — were taking down stock. Several institutional desks confirmed seeing real buy programs from family offices, hedge funds, and even a small number of long-only mutual funds that had been quietly waiting for federal policy clarity before stepping in.

The 24/7 Wall St. analysis published April 23 made the underrecognized point that the cannabis ETF universe has shrunk dramatically since the 2021 peak, with most cannabis ETFs delisted or merged. Only three meaningful US cannabis ETFs are still trading. That scarcity may concentrate capital flows into the surviving funds — and by extension, into their largest holdings.

The Stocks Analysts Still Like

Wall Street's post-rescheduling research has converged on a handful of names. Curaleaf is the most-mentioned long, with analysts pointing to the company's 34% year-to-date gain, scale advantages, and exposure to high-growth states like New York and Florida. Green Thumb Industries is the second-most-mentioned name, valued for its cash flow profile and disciplined capital allocation.

Trulieve gets bullish notes for its dominant Florida medical position, where the patient base is the largest in the country and where adult-use legalization remains a 2026 ballot question. Cresco Labs, despite the Tuesday spike, still trades at lower revenue multiples than GTI or Curaleaf, leaving analysts to argue there's room for further multiple expansion.

The Motley Fool's April 28 piece on cannabis stocks that could soar after rescheduling specifically called out Curaleaf, GTI, and Trulieve as the three names with the cleanest combination of tax-relief benefit, balance-sheet quality, and operational momentum. The note explicitly cautioned against penny-stock cannabis names that have spiked on rescheduling headlines without the cash flow profile to support the moves.

The Headwinds Schedule III Doesn't Fix

Sober-minded analysts are quick to point out what rescheduling does not solve. California cannabis sales are down 11% year-over-year. Wholesale flower prices have continued to grind lower in mature markets like Massachusetts and Michigan. The active cannabis license count nationwide has declined to 37,555, down 13% over two years, as small operators continue to fail.

Schedule III also does not fix interstate commerce — cannabis still cannot legally cross state lines, meaning the structural inefficiency of replicating cultivation, processing, and retail in every state remains. It does not provide explicit banking-law fixes; the SAFE Banking Act remains stalled in Congress despite renewed lobbying. And it does not address the patchwork of state regulatory regimes that drive much of the industry's compliance cost.

Perhaps most importantly, the rescheduling currently applies only to state-licensed medical cannabis. Recreational adult-use products remain Schedule I until and unless the broader DEA hearing scheduled for June 29 through July 15 produces a wider rule. Companies whose revenue is mostly recreational will not see the full 280E benefit until that proceeding completes — and most analysts now expect a final order on broader rescheduling by late Q4 2026.

What Comes Next

The next 60 days will be defined by federal registration filings. Operators that file within the priority window get expedited DEA review and the right to keep operating under state licenses while federal review proceeds. The first wave of approvals — expected by July or August — will be a major catalyst for the sector.

The June 29 DEA hearing on broader rescheduling is the second major event. A favorable ruling would extend 280E relief to recreational operations and trigger another leg of the rally. An unfavorable or delayed ruling would create a window of underperformance for recreational-heavy operators relative to medical-focused names.

Beyond policy, watch the Q1 2026 earnings season, which kicks off in mid-May. Analysts will be looking for forward guidance that incorporates the Schedule III tax benefit and for commentary on capital allocation — particularly whether MSOs use the freed-up cash flow for debt paydown, M&A, or shareholder returns.

Key Takeaways

• US cannabis MSOs rallied hard with Cresco Labs +19%, GTI +13.85%, and JUSHF +12.43% on rescheduling.
• The 280E tax benefit alone is worth roughly $500 million annually across the top five MSOs.
• Curaleaf is up 34% year-to-date with estimated annual tax savings near $116 million.
• Schedule III does not yet apply to recreational cannabis pending the June 29 DEA hearing.
• Wholesale price pressure, California weakness, and license declines remain headwinds despite the rally.

While the equity market prices in Schedule III, shoppers can use Budpedia's dispensary near me directory today — 7,400+ verified medical and recreational retailers across every legal state.

Explore cannabis news, find dispensaries, and join the community at Budpedia.